647 |
How To Disclose and What To Be Disclosed: Conflict of Interest for Physicians and Its Implication in Clinical Trial Conduct |
Ted Feldman |
Oct. 02. 08 |
646 |
FDA Perspectives of Clinical Trials in Interventional cardiology: Korean FDA |
Moo Song Lee |
Oct. 02. 08 |
645 |
FDA Perspectives of Clinical Trials in Interventional Cardiology: US FDA |
Angela Smith |
Oct. 02. 08 |
644 |
Nuts and Bolts of Clinical Trials: DSMB, Event Committees, Core Labs, Data Standards |
Ron Waksman |
Oct. 02. 08 |
643 |
Understanding of Clinical Trials in Interventional Cardiology: Trial Design Issues |
Ajay J. Kirtane |
Oct. 02. 08 |
642 |
CARESS-in-AMI |
Carlo Di Mario |
Sep. 26. 08 |
641 |
Treatment Modalities for Diagnosing and Treatment of Vulnerable Plaque |
Ron Waksman |
Sep. 26. 08 |
640 |
Reconciling Angiographic and Clinical Results After Stent Treatment: A Critical Appraisal and Recommendations for Clinical Assessments of Future Stents |
Jeffrey J. Popma |
Sep. 26. 08 |
639 |
Drug Eluting Stents: How Can We Know If "Newer" Is Actually "Better"? |
Mitchell W. Krucoff |
Sep. 26. 08 |
638 |
The Complex Relation Between Vulnerability and Ischemia |
Nico Pijls |
Sep. 26. 08 |